This last year has seen the approval of the first targeted treatments for acute myeloid leukemia (AML) - following decades with no new developments and a poor prognosis for most patients with the disease. The new drugs reflect the remarkable progress that has been made in our understanding of the pathophysiology of AML and its underlying cytogenetic and molecular abnormalities - which differ not only between patients but also within a patient over time and with treatment. 'Fast Facts: Acut...

This last year has seen the approval of the first targeted treatments for acute myeloid leukemia (AML) - following decades with no new developments and a poor prognosis for most patients with the disease. The new drugs reflect the remarkable progress that has been made in our understanding of the pathophysiology of AML and its underlying cytogenetic and molecular abnormalities - which differ not only between patients but also within a patient over time and with treatment. 'Fast Facts: Acut...